These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 6100605

  • 1. Safety and efficacy of enalapril. Summing up the evidence.
    Dollery CT.
    J Hypertens Suppl; 1983 Oct; 1(1):155-7. PubMed ID: 6100605
    [No Abstract] [Full Text] [Related]

  • 2. Evolution of angiotensin-converting enzyme inhibitors.
    Wyvratt MJ.
    Clin Physiol Biochem; 1988 Oct; 6(3-4):217-29. PubMed ID: 2849521
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ACE inhibitors: enalapril and captopril compared.
    Drug Ther Bull; 1985 Nov 18; 23(23):89-91. PubMed ID: 2998719
    [No Abstract] [Full Text] [Related]

  • 5. Captopril and enalapril: angiotensin converting enzyme (ACE) inhibitors.
    Ferguson RK, Vlasses PH, Riley LJ.
    Ration Drug Ther; 1984 Mar 18; 18(3):1-5. PubMed ID: 6093192
    [No Abstract] [Full Text] [Related]

  • 6. Enalapril: a new angiotensin-converting enzyme inhibitor.
    McRaith J, Fitz A.
    Iowa Med; 1986 Oct 18; 76(10):482, 484, 486-8. PubMed ID: 3023256
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB, Davies RO, Ferguson RK.
    Fed Proc; 1984 Apr 18; 43(5):1314-21. PubMed ID: 6323221
    [Abstract] [Full Text] [Related]

  • 9. [Enalapril--an oral angiotensin-converting enzyme inhibitor: its pharmacological properties and clinical use].
    Wiecek A, Grzeszczak W.
    Pol Tyg Lek; 1988 Feb 29; 43(9):279-83. PubMed ID: 2841654
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 29; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 12. [Angioneurotic edema caused by angiotensin-converting enzyme inhibitors: incidence, clinical characteristics, mechanisms of action].
    Wernze H.
    Z Kardiol; 1988 Oct 29; 77 Suppl 3():61-4. PubMed ID: 2850689
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Influence of the acetylcholinesterase inhibitors enalapril and captopril on exercise tolerance in hypertensive patients].
    Lai C, Onnis E, Pirisi R, Orani E, Soro A, Cherchi A.
    Cardiologia; 1988 Feb 29; 33(2):211-5. PubMed ID: 2834061
    [No Abstract] [Full Text] [Related]

  • 17. The clinical pharmacology of enalapril.
    Gomez HJ, Cirillo VJ, Jones KH.
    J Hypertens Suppl; 1983 Oct 29; 1(1):65-70. PubMed ID: 6100610
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians.
    Adewole AD, Ikem RT, Adigun AQ, Akintomide AO, Balogun MO, Ajayi AA.
    Cent Afr J Med; 1996 Aug 29; 42(8):253-5. PubMed ID: 8990572
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.